Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is set to disrupt the healthcare industry with its innovative blood test for early cancer detection, and the upcoming ASCO data drop and ongoing FDA PMA review will likely solidify its position in the market. GRAIL has strong growth potential, as evidenced by its Q1 beat with 56,000 Galleri tests and 50% revenue growth year-over-year. There are risks, such as potential FDA approval delays or limitations on reimbursement, but GRAIL has a solid financial position with $823M in cash and is taking steps to expand its institutional adoption through seamless EMR integration and a growing sales force.

Bears say

GRAIL is facing challenges with its ASP compression, leading to speculation that its near-term revenue may be limited. Additionally, the company's focus on price elasticity and discounting programs, while possibly increasing awareness, may hurt its bottom line. Furthermore, materiality in ESG performance may vary across sectors, making it difficult to fully evaluate the company's performance.

GRAIL Inc (GRAL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 8 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.